The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region
To assess the efficacy of latent tuberculosis (TB) treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test.
This is a consecutive case series of all T-SPOT.TB positive latent TB patients with presumed tuberculous uveitis managed with anti-tuberculous therapy (ATT) from 1 January 2000 to 31 December 2015. Patients with active TB or other known causes of uveitis, immunocompromised states and those followed up < 12 months were excluded. Descriptive statistics and hypothesis testing were performed, with a significance level of p < 0.05 taken.
Among the 75 T-SPOT.TB tests performed for uveitis, 14 cases were enrolled. Mycobacterium tuberculosis was isolated in none of the sputum and intraocular samples. Most cases had posterior uveitis (10/14 cases, 71.4%) and/or intermediate uveitis (9/14 cases, 64.3%). Vasculitis was predominantly occlusive. The mean presenting best-corrected visual acuity (BCVA) was 0.18, improving to 0.44 at 6 months (p = 0.03) and 0.40 at 12 months. (p = 0.03). At 1 year, remission of uveitis was achieved in 92.9%, in which none of them recurred at the last follow-up. High-dose systemic steroid was required in 50% of patients. Only 1 patient was steroid dependent at 18 months. The BCVA improvement in patients treated with or without steroid was comparable.
In a TB-endemic region with wide Bacille Calmette–Guerin vaccination coverage, ATT for immunocompetent uveitis patients with latent TB identified from T-SPOT.TB test can improve vision, induce long-term steroid-free remission, and prevent recurrence and systemic reactivation of TB in those who require steroid.
KeywordsTuberculosis Uveitis Diagnostic tests Therapeutics
Compliance with ethical standards
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
For this type of study formal consent is not required.
- 1.Centers for Disease Control and Prevention (2005) Trends in tuberculosis in United States, 2004. Morb Mortal Wkly Rep 54:245–249Google Scholar
- 8.American Thoracic Society (1981) Diagnostic standards and classification of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis 123:343Google Scholar
- 11.Centers for Disease Control and Prevention (1995) Essential components of a tuberculosis prevention and control program: recommendations of the advisory council for the elimination of tuberculosis. Morb Mortal Wkly Rep 44:1–16Google Scholar
- 12.Tam CM, Leung CC (2000) Cessation of the BCG (Bacille Calmette Guerin) revaccination programme for primary school children in Hong Kong. Public Health Epidemiol Bull 9(3):25–27Google Scholar
- 15.La Distia Nora R, Van Velthoven ME, Ten Dam-van Loon NH, Misotten T, Bakker M, Van Hagen MP, Rothova A (2014) Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB Gold In-Tube test in a country nonendemic for tuberculosis. Am J Ophthalmol 157:754–761CrossRefGoogle Scholar
- 17.Ang M, Kiew SY, Wong WL, Chee SP (2014) Discordance of two interferon-gamma release assays and tuberculin skin test in patients with uveitis. Br J Ophthalmol 98:1694–1753Google Scholar
- 18.Gineys R, Bodaghi B, Carcelain G, Cassoux N, le Boutin TH, Amoura Z et al (2011) QuantiFERON-TB gold cut-off value: implications for the management of tuberculosis-related ocular inflammation. Am J Ophthalmol 152(433–40):e1Google Scholar
- 22.Heng JE, Vorwerk CK, Lessell E, Zurakowski D, Levin LA, Dreyer EB (1999) Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. Invest Opthalmol Vis Sci 40:190–196Google Scholar
- 23.Kass I (1965) Chemotherapy regimens used in retreatment of pulmonary tuberculosis II. Observations on the efficacy of combinations of ethambutol, capreomycin and companion drugs, including 4–4 diisoamyloxythiosemicarbanilide. Tubercle 46:66–77Google Scholar